Home › Prostate Cancer › Oklahoma
Prostate Cancer clinical trials in Oklahoma
24 studies for Prostate Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03866382Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Oklahoma Proton Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 29, 2026 · NCT01492972A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hightower Clinical, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07213674Protoacoustic Imaging For 3D Mapping
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07832617The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Utica Park Urology, Tulsa
Recruiting
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urologic Specialists, Tulsa
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 2, 2026 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06632977Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 to 100 · Men · Updated Aug 26, 2026 · NCT06960798Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Aug 19, 2026 · NCT04423211A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
- University of Oklahoma HSC, Oklahoma City
Recruiting
Ages 18 and older · Men · Updated Apr 1, 2026 · NCT06651359Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Men · Updated Jan 29, 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Jan 22, 2026 · NCT06470243Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT07014618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Connect2Care: Prostate Cancer Education and Screenings for African American Men
- TSET Health Promotion Research Center, Oklahoma City
Recruiting
Ages 45 to 69 · Men · Updated Sep 25, 2025 · NCT07055165Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2025 · NCT03678025A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05932862From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.